CClinicalTrials.gg
RecruitingNCT07721571Updated Oct 6, 2026

Nephrostomy Tract Infiltration for Pain Control After PCNL

An interventional study of Bupivacaine and Intravenous Tramadol and Paracetamol in Postoperative Pain and Kidney Calculi, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Hitit University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jul 2026; still recruiting 2 months later.
Updated Oct 6, 2026Eligibility revisedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This prospective, randomized, controlled clinical trial aims to evaluate the effectiveness of nephrostomy tract local anesthetic infiltration for postoperative pain control in patients undergoing prone percutaneous nephrolithotomy. Eligible patients will be randomly assigned to either a control group receiving standard systemic postoperative analgesia or an intervention group receiving standard analgesia plus infiltration of 20 mL of 0.25% bupivacaine along the nephrostomy tract at the end of surgery. Postoperative pain will be assessed using the Visual Analog Scale at 1, 6, 12, and 24 hours. Secondary outcomes will include time to first analgesic requirement, total opioid consumption during the first 24 hours, need for rescue analgesia, time to mobilization, length of hospital stay, and treatment-related complications. The study is designed to determine whether nephrostomy tract infiltration provides a simple, safe, and effective adjunct for reducing pain and analgesic consumption after percutaneous nephrolithotomy.

02

Conditions studied

  • Postoperative Pain
  • Kidney Calculi

Keywords

  • local anesthetic infiltration
  • Percutaneous nephrolithotomy
  • peritubal infiltration
  • postoperative pain
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Hitit University is the lead sponsor of 79 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 to 75 years
  • Scheduled to undergo elective percutaneous nephrolithotomy in the prone position
  • Classified as American Society of Anesthesiologists (ASA) physical status I-III
  • Able to understand and complete postoperative pain assessments using the Visual Analog Scale (VAS)
  • Willing to participate in the study
  • Provision of written informed consent

Exclusion criteria

Exclusion Criteria:

  • Known allergy or hypersensitivity to bupivacaine or other local anesthetic agents
  • Coagulopathy or clinically significant bleeding disorder
  • Chronic opioid use
  • History of a neurological disorder that may affect pain perception or assessment
  • Neurological or psychiatric condition preventing reliable postoperative pain assessment
  • Active urinary tract infection or sepsis
  • American Society of Anesthesiologists (ASA) physical status IV or higher
  • Requirement for multiple percutaneous access tracts
  • Bilateral percutaneous nephrolithotomy
  • Requirement for postoperative intensive care
  • Refusal or inability to provide written informed consent
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Nephrostomy Tract Bupivacaine Infiltration

    Participants in this arm will receive standard postoperative systemic analgesia. In addition, at the end of percutaneous nephrolithotomy, 20 mL of 0.25% bupivacaine will be infiltrated along the nephrostomy tract, including the skin, subcutaneous tissue, muscular layers, and tissues surrounding the nephrostomy tract.

    Drug: Bupivacaine · Drug: Intravenous Tramadol and Paracetamol

  • Active comparator
    Standard Systemic Analgesia

    Participants in this arm will receive the standard postoperative systemic analgesia protocol, including intravenous tramadol and intravenous paracetamol. Rescue opioid analgesia will be administered when clinically required. No local or regional analgesic intervention will be performed.

    Drug: Intravenous Tramadol and Paracetamol

Interventions

  • DrugBupivacaine

    A total of 20 mL of 0.25% bupivacaine will be administered by local infiltration along the nephrostomy tract at the end of surgery. The infiltration will include the skin, subcutaneous tissue, muscular layers, and tissues surrounding the nephrostomy tract.

    Also known as: Bupivacaine hydrochloride, Nephrostomy tract local anesthetic infiltration, Peritubal bupivacaine infiltration

  • DrugIntravenous Tramadol and Paracetamol

    Standard postoperative systemic analgesia consisting of intravenous tramadol and intravenous paracetamol will be administered according to the institutional analgesia protocol. Rescue opioid analgesia will be provided when clinically required.

    Also known as: Standard postoperative analgesia, Intravenous tramadol and acetaminophen

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity Assessed Using the Visual Analog Scale

    Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS). Patients will rate their pain on a scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. VAS scores will be compared between the nephrostomy tract bupivacaine infiltration group and the standard systemic analgesia group.

    Time frame: At 1, 6, 12, and 24 hours after surgery

Secondary outcomes

  1. Time to First Rescue Analgesic Requirement

    The time from the end of surgery to the first administration of rescue analgesic medication will be recorded in minutes. A longer duration indicates a prolonged postoperative analgesic effect.

    Time frame: From the end of surgery until the first rescue analgesic administration, within the first 24 postoperative hours

  2. Total Opioid Consumption During the First 24 Postoperative Hours

    The total amount of opioid analgesics administered during the first 24 hours after surgery will be recorded. When different opioid agents are used, doses will be converted to intravenous morphine milligram equivalents for comparison between groups.

    Time frame: During the first 24 hours after surgery

  3. Requirement for Rescue Analgesia

    The number and proportion of participants requiring at least one dose of rescue analgesic medication will be compared between the study groups.

    Time frame: During the first 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • Department of Urology, Hitit University Çorum Erol Olçok Training and Research Hospital, Çorum, Türkiye
    Çorum, Çorum 19040, Turkey (Türkiye)
    • MUSA EKİCİ · Contact · musaekici@hitit.edu.tr · +90 505 751 6341
    • AHMET TAŞCI · Sub investigator
    • METİN KIZGIN · Sub investigator
    Recruiting
08

References and documents

Publications

  • Shah HN, Shah RH, Sodha HS, Khandkar AA, Gokhale A. A randomized control trial evaluating efficacy of nephrostomy tract infiltration with bupivacaine after tubeless percutaneous nephrolithotomy. J Endourol. 2012 May;26(5):478-83. doi: 10.1089/end.2011.0465. Epub 2011 Dec 22. PubMed 22191494 ↗
  • Arshad Z, Zaidi SZ, Jamshaid A, Qureshi AH. Post operative pain control in percutaneous nephrolithotomy. J Pak Med Assoc. 2018 May;68(5):702-704. PubMed 29885165 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Also revised
eligibility
Show all 1 update
  1. Oct 6, 2026
    Eligibility Criteria revised

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07721571
Lead sponsor
Hitit University
Responsible party
Mustafa Serdar CAGLAYAN (Assistant Professor, MD, Hitit University) — Principal investigator
First posted
Jul 23, 2026
Start date
Jul 17, 2026
Primary completion
Jan 11, 2027 (estimated)
Completion
Jun 11, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

MUSTAFA SERDAR ÇAĞLAYAN
Contact
serdar.09.09@hotmail.com
+905074311951

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion